| Literature DB >> 19044202 |
Soshana Behrstock1, Allison D Ebert, Sandra Klein, Melanie Schmitt, Jeannette M Moore, Clive N Svendsen.
Abstract
The use of human neural progenitor cells (hNPC) has been proposed to provide neuronal replacement or astrocytes delivering growth factors for brain disorders such as Parkinson's and Huntington's disease. Success in such studies likely requires migration from the site of transplantation and integration into host tissue in the face of ongoing damage. In the current study, hNPC modified to release glial cell line-derived neurotrophic factor (hNPCGDNF) were transplanted into either intact or lesioned animals. GDNF release itself had no effect on the survival, migration, or differentiation of the cells. The most robust migration and survival was found using a direct lesion of striatum (Huntington's model) with indirect lesions of the dopamine system (Parkinson's model) or intact animals showing successively less migration and survival. No lesion affected differentiation patterns. We conclude that the type of brain injury dictates migration and integration of hNPC, which has important consequences when considering transplantation of these cells as a therapy for neurodegenerative diseases.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19044202 PMCID: PMC2650839 DOI: 10.3727/096368908786516819
Source DB: PubMed Journal: Cell Transplant ISSN: 0963-6897 Impact factor: 4.064